drugset / Trial / NCT04814446
Nonavalent HPV Vaccine in the Treatment of Difficult-to-treat Palmo-plantar Warts
RandomizedParallel-groupDouble-blindTreatment
Summary
Cutaneous viral warts are very common and are caused by the human papilloma virus (HPV). Most people experience warts in one form or another at some point in their lives. Cutaneous warts are related to different types of HPV. For the palms and soles, HPV 2 has been the most frequently found but HPV 1, 4, 27, and 57 have also been described. Our hypothesis is that vaccination by nonavalent vaccine against HPV could lead to a complete resolution of difficult-to-treat palmo-plantar warts patients of more than 15 years and 3 months of age.
Timeline
- Start
- 2022-06-29
- Primary completion
- 2025-06-29
- Completion
- 2026-06-29
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Vaccination | Vaccine | 0.5 ml | Intramuscular |